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Abstract
Background: microRNA (miRNA) are important regulators of gene expression. In patients with ischemic stroke we have
previously shown that differences in immune cell gene expression are present. In this study we sought to determine the
miRNA that are differentially expressed in peripheral blood cells of patients with acute ischemic stroke and thus may
regulate immune cell gene expression.
Methods: miRNA from peripheral blood cells of forty-eight patients with ischemic stroke and vascular risk factor controls
were compared. Differentially expressed miRNA in patients with ischemic stroke were determined by microarray with qRT-
PCR confirmation. The gene targets and pathways associated with ischemic stroke that may be regulated by the identified
miRNA were characterized.
Results: In patients with acute ischemic stroke, miR-122, miR-148a, let-7i, miR-19a, miR-320d, miR-4429 were decreased and
miR-363, miR-487b were increased compared to vascular risk factor controls. These miRNA are predicted to regulate several
genes in pathways previously identified by gene expression analyses, including toll-like receptor signaling, NF-kb signaling,
leukocyte extravasation signaling, and the prothrombin activation pathway.
Conclusions: Several miRNA are differentially expressed in blood cells of patients with acute ischemic stroke. These miRNA
may regulate leukocyte gene expression in ischemic stroke including pathways involved in immune activation, leukocyte
extravasation and thrombosis.
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Introduction
microRNA (miRNA) are important regulators of gene expres-
sion and play important roles in the initiation and progression of
several diseases. Indeed, dysregulation of miRNA in the immune
system has been linked to chronic lymphocytic leukemia (miR-15a,
miR-16) [1], rheumatoid arthritis (miR-146a) [2], and multiple
sclerosis (miR-326) [3]. In stroke miRNA may play an important
regulatory role, particularly given the known effects of miRNA on
the immune system and vasculature [4]. Preliminary studies
indicate miRNA are dysregulated in the blood and brain of rodent
ischemic stroke [5–7]. However, additional study is required to
better understand miRNA in patients with acute ischemic stroke
and their regulation of genes and pathways involved in cerebro-
vascular disease.
miRNA are short (,17–25 nucleotides long) non-protein coding
ribonucleic acids. They regulate gene expression at multiple
epigenetic levels including mRNA degradation, mRNA seques-
tration, translational repression and transcriptional repression [8].
In patients with acute ischemic stroke changes in blood gene
expression are present and correspond to differences in the
immune and coagulation systems [9–12]. Given miRNA are
predicted to regulate .60% of known mRNA [13], many of the
genes expressed in acute ischemic stroke are likely regulated by
miRNA. In this study we sought to determine whether miRNA are
differentially expressed in patients with acute cerebral ischemia
and thus may be important regulators of leukocyte gene expression
in ischemic stroke.
Methods
Study Subjects
The study protocol was approved by the University of
California Davis Institutional Review Board and all subjects
provided informed written consent. Patients were recruited from
the University of California Davis from November 2010 to
November 2012. There were 24 patients with acute ischemic
stroke and 24 vascular risk factor controls. Stroke diagnosis
required consensus of two board certified neurologists and
restricted diffusion on brain MRI (positive DWI-MRI). Patients
with infection (current or within 2 weeks of stroke), immunosup-
pressive therapy, lymphoma, leukemia, or treatment with throm-
bolytic therapy were excluded from study. Control subjects had
vascular risk factors without prior history of stroke, myocardial
infarction or peripheral vascular disease.
PLOS ONE | www.plosone.org 1 June 2014 | Volume 9 | Issue 6 | e99283
microRNA Isolation
Blood was collected in PAXgene tubes (Pre-AnalytiX/BD) from
a venous blood draw performed within 72 hours of stroke onset
and stored frozen at 280uC. PAXgene tubes stabilize RNA in
blood, which is predominantly from circulating leukocytes (e.g.
granulocytes, monocytes, B-cells, T-cells) and megakaryocytes.
RNA was isolated according to the manufacturer’s protocol
(PAXgene blood miRNA kit; Pre-AnalytiX). Quantity and quality
of RNA was determined by Nano-Drop (Thermo Fisher) and
Agilent 2100 Bioanalyzer (Agilent). Samples required A260/A280
absorbance ratio $1.8, A260/A230 $1.8, 28S/18S rRNA ratio $
1.8, and an RNA integrity number $8.
microRNA Analysis
microRNA were initially screened by microarray with identified
candidates evaluated by qRT-PCR. For the microarray analysis,
200 ng of total RNA was labeled using FlashTag Biotin HSR
labeling kits (Affymetrix, CA) with no amplification, hybridized to
Affymetrix Gene Chip miRNA 3.0 Arrays, and scanned using an
Affymetrix GCS3000 Gene Array Scanner according to manu-
facturer’s protocol (Affymetrix, Santa Clara, CA) (GSE55937).
Data were analyzed in Partek Genomics Suite 6.6, normalized
using RMA, and log2 transformed. Subjects with acute ischemic
stroke were compared to controls with adjustment for microarray
batch using ANOVA. miRNA with a fold change .|1.2| and p,
0.05 were evaluated by qRT-PCR.
TaqMan microRNA assays (Applied Biosystems, Foster City,
CA) were used to evaluate candidate miRNA identified by
microarray. Total RNA (25 ng per sample) was converted into
cDNA using RT Primers and TaqMan microRNA RT Kit
(Applied Biosystems). cDNA was amplified using RT PreAmp
Primers and Taqman PreAmp Master Mix (Applied Biosystems).
Diluted PreAmp product was mixed with TaqMan Universal PCR
Master Mix and Taqman miRNA assay and run using an Applied
Biosystems 7900HT real-time PCR instrument (Applied Biosys-
tems). U75 was used as the endogenous control. Cycle thresholds
were determined using RQ manager and miRNAs where 95%
had a raw cycle threshold score .35 were excluded (Schmittgen
et al, 2008). Analysis was performed in Partek Genomics Suite
(Partek, St Louis, MI, USA). Differentially expressed miRNAs in
ischemic stroke compared to controls had a fold change .|1.5|
and a false discovery rate (FDR) corrected p-value,0.05.
microRNA Targets
mRNA targets of the identified miRNA were determined using
target gene databases (Target Scan 6.0 human, Tarbase,
miRecords, Ingenuity Pathway Analysis). mRNA were considered
targets if there was prior experimentally observed regulation by
miRNA or if they were predicted with high probability to be gene
targets. mRNA targets of the identified miRNA were compared to
genes and pathways associated with human ischemic stroke to
evaluate potential miRNA regulation of leukocyte gene expression
in ischemic stroke [9–12].
Results
Characteristics of the 24 patients with acute ischemic stroke and
24 control subjects are shown in Table 1. The mean age was 63.1
years and 50% were female. The study population was ethnically
diverse with 68.7% Caucasian, 12.5% African American, 6.3%
Asian, and 12.5% of other race. No statistically significant
differences with respect to demographic or vascular risk factors
were present between patients with ischemic stroke and controls
(Table 1). The median time from stroke onset to blood draw was
27.4 hours (IQR 10.5–46.0). There were 8 (33%) cardioembolic
strokes, 8 (33%) large vessel strokes, and 8 (33%) small vessel
lacunar strokes.
There were eight miRNA differentially expressed between acute
ischemic stroke and vascular risk factor controls (Figure 1, Figure
S1, Table S1). Six miRNA had increased expression miR-122 (FC-
2.29, FDR p-value 0.047), miR-148a (FC -2.05, FDR p-value
0.009), let-7i (FC -2.07, FDR p-value 0.023), miR-19a (FC -1.66,
FDR p-value 0.030), miR-320d (FC -1.70, FDR p-value 0.020),
miR-4429 (FC -1.61, FDR p-value 0.034); and two miRNA had
decreased expression miR-363 (FC 3.61, FDR p-value 0.037),
miR-487b (FC 2.66, FDR p-value 0.044). These miRNA are
either known to regulate or are predicted with high probability to
regulate the expression of several genes in pathways associated
with ischemic stroke including NF-kb signaling, toll-like receptor
signaling, leukocyte extravasation, interleukin signaling, trans-
forming growth factor-b signaling, and the prothrombin activation
pathway (Figure 2, Table S2). At the level of biological systems,
several of the miRNA have been shown to regulate aspects of the
immune system and coagulation system as presented in the
discussion.
Discussion
We identified miR-122, miR-148a, let-7i, miR-19a, miR-320d,
miR-4429 to be decreased and miR-363, miR-487b to be
increased in blood cells of patients with acute ischemic stroke.
These miRNA may be important regulators of leukocyte gene
expression in acute ischemic stroke. They are predicted to regulate
a number of genes and pathways associated with ischemic stroke
including immune activation, leukocyte extravasation and throm-
bus formation.
Table 1. Characteristics of ischemic stroke and vascular risk factor control study subjects.
Characteristic Control (n = 24) Ischemic Stroke (n =24) p-value
Age years (SD) 63.8 (8.5) 62.4 (8.1) 0.38
Gender male n(%) 12 (50.0%) 12 (50.0%) 1.00
Hypertension History n(%) 21 (87.5%) 18 (75.0%) 0.28
Diabetes History n(%) 8 (33.3%) 7 (29.2%) 0.76
Hyperlipidemia n(%) 16 (66.7%) 16 (66.7%) 1.00
Smoker n(%) 5 (20.8%) 9 (37.5%) 0.20
Atrial Fibrillation n(%) 6 (25.0%) 5 (20.8%) 0.74
doi:10.1371/journal.pone.0099283.t001
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The role of miRNA in patients with ischemic stroke is a
developing field, with growing interest for their potential
biomarker and therapeutic applications [14]. This report adds to
our understanding of miRNA expression and gene regulation in
acute cerebral ischemia. Prior studies have reported miRNA
expression in patients with subacute and chronic ischemic stroke.
Within 7-14 days of stroke onset circulating plasma levels of miR-
21, miR-221 [15], and miR-145 [16] are increased whereas miR-
210 is decreased [17]. miRNA can also be studied in blood at the
intracellular level from circulating leukocytes and other blood cells.
In the one stroke study of blood cells, 157 miRNA were reported
to be differentially expressed in young patients 6–18 months after
stroke when compared to healthy controls [18]. In the current
study we report the cellular blood miRNA expressed in patients
with acute ischemic stroke. Several of the identified miRNA in
acute cerebral ischemia overlap with those reported in subacute
and chronic stroke including let-7i, miR-19a, miR-320d, miR-363,
and miR-487b. However, additional study is required to delineate
the time course of miRNA expression following ischemic stroke
and the relationship between plasma and cellular blood miRNA.
miRNA Regulation of Leukocyte Activation
miRNA may regulate activation of the immune system in
ischemic stroke. Following ischemic brain injury, peripheral
leukocytes are activated via release of cytokines, chemokines,
and Damage Associated Molecular Pattern molecules (DAMPs).
We previously have found that genes involved in TLR signaling
and NFKB signaling are differentially expressed in patients with
acute ischemic stroke [9–12]. Several of the cellular blood miRNA
identified act on genes in these pathways including let-7i, miR-
19a, miR-320 (Figure 2). These miRNA may modulate immune
activation and inflammatory response following stroke. Indeed,
several of these miRNA have a known biological effect on
leukocytes. Let-7i regulates toll-like receptor signaling in mono-
cytes, modulates the differentiation of dendritic cells, and directs
T-cells toward a Th1 phenotype [19,20]. miR-122 regulates the
expression of peroxiredoxin 2, a DAMP involved in immune
activation post stroke [21]. miRNA-148 fine tunes immune
response by altering cytokine production (IL6, TNF-a, IL-12,
TNFSF7), T-cell proliferation, MHC II expression, and dendritic
cell antigen presentation [22,23]. miR-19b is reported to
negatively regulate inflammation in humans and activate expres-
sion of TLR2 and TLR4 [24,25]. Thus miR-19a may promote
inflammatory response in ischemic stroke.
miRNA Regulation of Leukocyte Extravasation
miRNA may also regulate genes involved in leukocyte
extravasation following ischemic stroke. We previously have found
that genes involved in leukocyte adhesion and blood brain barrier
disruption (MMPs) are differentially expressed in patients with
acute ischemic stroke [9–12]. Of the cellular blood miRNA
identified, several may regulate these genes. miR-148 is known to
regulate leukocyte expression of the adhesion molecule LFA-1 and
the matrix metalloproteases MMP10, MMP13, and MMP-15
[23]. miR-487b family members facilitate cellular invasion by up-
regulating MMPs in myeloid cells [26]. Of note, miR-487b is
induced by hypoxia [27]. miR-320 regulates ischemic-reperfusion
injury in cardiac tissue and inhibiting miR-320 reduces infarct size
in myocardial ischemia [28]. miR-320 targets ETS2, a transcrip-
tion factor that regulates the expression of several genes important
to leukocyte extravasation post-stroke including MMP-9, MMP-3,
MMP-13, ANGPT1, and TNF [29,30]. miRNA-19a regulates
MMP-3 via TLR2 [24] and has angiogenic roles that may
contribute to blood brain barrier breakdown and vascular
remodeling post stroke [31].
miRNA Regulation of Thrombus Formation
Aspects of thrombus formation may also be regulated by
miRNA in ischemic stroke. miRNA are known to regulate
coagulation and platelets [32,33]. Tissue factor is a central
component in the coagulation cascade and monocytes are a major
source. miR-19a acts on tissue factor pathway inhibitor (TFPI) to
reduce tissue factor activity and prevent clot formation. Thus, in
ischemic stroke miR-19a may modulate thrombus formation
through effects on TFPI. Another gene that may be regulated by
miRNA in ischemic stroke is SERPINE1 (plasminogen activator
inhibitor-1 (PAI-1). SERPINE1 codes for the principal inhibitor of
tissue plasminogen activator (tPA) and urokinase (uPA), which act
on plasminogen to promote fibrinolysis. miR-148a and miR-19a
Figure 1. Fold change in microRNA that are significantly differentially expressed in patients with acute ischemic stroke compared
to controls with vascular risk factors (FDR,0.05). Error bars indicate standard error. Expression determined by qRT-PCR.
doi:10.1371/journal.pone.0099283.g001
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both target SERPINE1 and may regulate the activity of
endogenous tPA in ischemic stroke. Other coagulation factors
that may be regulated by miRNA in ischemic stroke include
thrombin (let-7i), coagulation factor 8 (miR-122), and coagulation
factor 3 (miR-148, miR-19a).
Strengths of this study include a comparison of ischemic stroke
patients to controls similar in age and vascular risk factors,
evaluation of all known miRNA by microarray with qRT-PCR
confirmation, and the use of PAXgene tubes which reduce
changes that occur as a result of RNA degradation. This
preliminary study has limitations. Sample size remains small; thus
additional studies in larger cohorts using multiple methods to
measure and confirm miRNA expression are required. This study
focused on all ischemic stroke. However, certain miRNA may be
differentially expressed by subtype of ischemic stroke, which will
require a larger cohort to examine. The gene targets of the
miRNA were identified using target databases. Additional studies
are required to experimentally evaluate miRNA gene targets and
determine their functional role in ischemic stroke.
In conclusion, several miRNA are differentially expressed in
blood cells of patients with acute ischemic stroke. These miRNA
are predicted to regulate gene expression and pathways in blood
that are associated with ischemic stroke. With additional study, the
identified miRNA may serve as markers of cerebral ischemia or
provide novel methods to modulate the immune and coagulation
systems in ischemic stroke.
Figure 2. Genes and their microRNA targets in the NF-kB and toll-like receptor signaling pathways. microRNA were identified in the
current study as differentially expressed in ischemic stroke, and are predicted to target genes based on prior observation or high predicted
probability. Abbreviations: GFR, Growth factor receptor; IKK, Inhibitor of nuclear factor kappa-B kinase; IRAK, Interleukin-1 receptor-associated kinase;
MAPK, Mitogen-activated protein kinase; MYD88, Myeloid differentiation primary response 88; PI3K, Phosphatidylinositide 3-kinase; TLR, Toll like
receptor; TRAF, TNF receptor associated factor.
doi:10.1371/journal.pone.0099283.g002
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Supporting Information
Figure S1 Relative microRNA expression in patients with acute
ischemic stroke compared to vascular risk factor controls.
Expression determined by qRT-PCR relative to U75, with lowest
expressing miRNA assigned a value of 1.
(TIF)
Table S1 microRNA differentially expressed between acute
ischemic stroke and vascular risk factor controls.
(PDF)
Table S2 Pathways previously associated with ischemic stroke by
gene expression analysis of blood and the microRNA targeting
genes in that pathway. Gene targets are experimentally observed
or predicted with high probability to be targets.
(PDF)
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